American Century Companies Inc. Raises Position in Illumina, Inc. (NASDAQ:ILMN)

American Century Companies Inc. grew its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.5% during the fourth quarter, Holdings Channel reports. The fund owned 226,852 shares of the life sciences company’s stock after purchasing an additional 23,338 shares during the period. American Century Companies Inc.’s holdings in Illumina were worth $30,314,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Bleakley Financial Group LLC bought a new position in Illumina in the fourth quarter worth $751,000. Zacks Investment Management purchased a new stake in shares of Illumina in the 3rd quarter worth about $2,924,000. Van ECK Associates Corp increased its stake in shares of Illumina by 17.5% in the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock worth $20,347,000 after acquiring an additional 22,718 shares in the last quarter. Strategic Financial Concepts LLC purchased a new position in Illumina during the 4th quarter valued at about $1,464,000. Finally, Allworth Financial LP boosted its stake in Illumina by 720.7% during the fourth quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock worth $1,001,000 after acquiring an additional 6,263 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on ILMN. Hsbc Global Res downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Morgan Stanley lowered their price objective on Illumina from $150.00 to $136.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 11th. Guggenheim dropped their target price on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Canaccord Genuity Group reduced their price target on Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, March 11th. Finally, HSBC cut shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Illumina currently has an average rating of “Moderate Buy” and an average target price of $140.90.

Illumina Stock Down 2.8 %

ILMN stock opened at $80.00 on Friday. The company has a market cap of $12.67 billion, a price-to-earnings ratio of -10.42, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The business’s 50-day moving average is $102.80 and its two-hundred day moving average is $126.79. Illumina, Inc. has a fifty-two week low of $79.30 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.